Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials

医学 中止 不利影响 入射(几何) 耐受性 内科学 安慰剂 人口 肌酐 析因分析 危险系数 置信区间 病理 物理 替代医学 光学 环境卫生
作者
R. Scott Wright,Wolfgang Köenig,Ulf Landmesser,Lawrence A. Leiter,Frederick J. Raal,Gregory G. Schwartz,Anastasia Lesogor,Pierre Maheux,Christian Stratz,Xiao Zang,Kausik K. Ray
出处
期刊:Journal of the American College of Cardiology [Elsevier BV]
卷期号:82 (24): 2251-2261 被引量:34
标识
DOI:10.1016/j.jacc.2023.10.007
摘要

Inclisiran is a small interfering RNA agent to lower low-density lipoprotein cholesterol. The purpose of this study was to provide reliable evidence to date on the long-term safety profile of inclisiran. This post hoc analysis comprised patients treated with 300 mg inclisiran sodium or placebo in the completed (ORION-1, -3, -5, -9, -10, and -11) and ongoing (ORION-8) trials. Exposure-adjusted incidence rates and Kaplan-Meier estimates of cumulative incidence of reported treatment-emergent adverse events (TEAE), abnormal laboratory measurements, and incidence of antidrug antibodies were analyzed. This analysis included 3,576 patients treated with inclisiran for up to 6 years and 1,968 patients treated with placebo for up to 1.5 years, with 9,982.1 and 2,647.7 patient-years of exposure, respectively. Baseline characteristics were balanced between groups. Kaplan-Meier analyses showed that TEAEs that were serious or led to discontinuation; hepatic, muscle, and kidney events; incident diabetes; and elevations of creatine kinase or creatinine accrued at a comparable rate between groups for up to 1.5 years, with similar trends continuing for inclisiran beyond this period. Numerically fewer major cardiovascular events reported as TEAEs occurred with inclisiran during this period. Treatment-induced antidrug antibodies were uncommon with inclisiran (4.6%), with few of these persistent (1.4%) and not associated with greater incidence of TEAEs leading to study drug discontinuation or serious TEAEs. Long-term treatment with inclisiran was well tolerated in a diverse population, without new safety signals, supporting the safety of inclisiran in patients with dyslipidemia.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
阿绿发布了新的文献求助10
4秒前
5秒前
5秒前
雨柏完成签到 ,获得积分10
5秒前
wanci应助qwe1108采纳,获得10
6秒前
明天过后完成签到,获得积分10
8秒前
jin完成签到,获得积分10
9秒前
yhy完成签到 ,获得积分10
10秒前
黑色卡布奇诺完成签到,获得积分20
10秒前
tanglu发布了新的文献求助10
10秒前
可爱的函函应助梁大海采纳,获得10
10秒前
成就绮琴完成签到 ,获得积分10
11秒前
xicifish完成签到,获得积分10
11秒前
目光之澄完成签到,获得积分10
12秒前
wanci应助研友_ndDPBn采纳,获得10
12秒前
耍酷的白梦完成签到,获得积分10
13秒前
miracle完成签到 ,获得积分10
14秒前
coding完成签到,获得积分10
15秒前
16秒前
犹豫水蓝完成签到,获得积分10
17秒前
yin完成签到,获得积分10
17秒前
JUGG完成签到,获得积分10
17秒前
CipherSage应助阿湫采纳,获得10
18秒前
FIN应助手机采纳,获得20
18秒前
星辰大海应助东黎采纳,获得10
18秒前
量子星尘发布了新的文献求助10
18秒前
wujingshuai完成签到,获得积分10
19秒前
少年完成签到,获得积分10
19秒前
星辰大海应助ficus_min采纳,获得10
20秒前
小柒柒完成签到,获得积分10
21秒前
sdfwsdfsd完成签到,获得积分10
22秒前
亮仔完成签到,获得积分10
23秒前
土豆丝发布了新的文献求助10
23秒前
ylw完成签到,获得积分20
24秒前
西门明雪完成签到,获得积分10
24秒前
24秒前
烟花应助万松辉采纳,获得10
25秒前
爆米花应助不站在雾里采纳,获得10
25秒前
yy完成签到,获得积分20
26秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038524
求助须知:如何正确求助?哪些是违规求助? 3576221
关于积分的说明 11374737
捐赠科研通 3305912
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892688
科研通“疑难数据库(出版商)”最低求助积分说明 815048